Evidence brief · intervention
Stem-cell therapy
Mesenchymal stem cells (MSCs)—multipotential progenitor cells capable of self-renewal and differentiating into various lineages—represent a promising tool for regenerative medicine, tissue engineering, and cellular therapy [1, 3, 5, 7, 8]. While bone marrow was the initial source for MSC isolation, alternative sources like umbilical cord blood and adipose tissue are heavily investigated to circumvent limitations such as invasive donation procedures and the age-related decline in MSC number and differentiation potential [1]. Beyond direct differentiation, MSCs exhibit migratory abilities, secrete protective factors, and display immunoprivileged and immunomodulatory properties [7, 8].
Despite their therapeutic potential, significant challenges remain regarding cell sourcing, in vitro expansion, and replicative senescence(definition) [10]. Replicative senescence during culture limits the potency and consistency of MSCs, prompting the development of strategies like partial reprogramming(definition)—such as novel circRNA platforms designed to rejuvenate aged MSCs without unintended pluripotent conversion [10]. Other open avenues include optimizing engineered tissue alternatives to conventional bone grafts [2] and utilizing human umbilical cord MSC-derived exosomes loaded with compounds like pterostilbene to enhance neuroprotection and targeted delivery across the blood-brain barrier [9]. Additionally, distinct from therapeutic adult MSCs, cancer stem cells (CSCs) are targeted in oncology due to their driving role in tumor recurrence, metastasis, and resistance [4].
The strength of evidence supporting the foundational biology, multilineage differentiation, and immunomodulatory capacities of MSCs is robust and backed by decades of preclinical and clinical exploration [1, 3, 5, 7, 8]. However, evidence regarding advanced optimization techniques—such as specific exosome delivery systems [9] and safe partial reprogramming(definition) platforms [10]—is emerging and currently relies on early-stage in vitro and model organism investigations.
Sources
- [1] Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose Tissue
- [2] Bone Tissue Engineering: Recent Advances and Challenges
- [3] Mesenchymal stem cell perspective: cell biology to clinical progress
- [4] Targeting cancer stem cell pathways for cancer therapy
- [5] Adult mesenchymal stem cells for tissue engineering versus regenerative medicine
- [6] Stem cells: past, present, and future
- [7] Immunomodulatory properties of mesenchymal stromal cells
- [8] Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC
- [9] Engineered hUC-MSC exosomes loaded with pterostilbene induce Nrf2/SKN-1-dependent microglial M2 polarization and neuroprotection in Alzheimer's disease in vitro and in Caenorhabditis elegans.
- [10] A circRNA platform for safe partial reprogramming and rejuvenation of mesenchymal stem cells without pluripotent conversion.